Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of Lung Adenocarcinoma by Phosphorylated FOXN3-Mediated Transcriptional Inactivation of p53.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Multiple regulatory roles of UNC93B1 in innate immunity.

Cellular signalling·2026
Same author

The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases.

Cellular and molecular life sciences : CMLS·2026
Same author

Comparative and subtractive genomics reveals novel therapeutic targets in cystic fibrosis-associated multidrug-resistant Pandoraea sputorum.

Diagnostic microbiology and infectious disease·2026
Same author

Glycosylation as a dynamic regulator of RLR and cGAS-STING innate immune signalling pathways.

Communications biology·2026
Same author

TRIM69 potentiates the cGAS-STING signalling pathway by promoting STING ubiquitination.

Cellular signalling·2026

Related Experiment Video

Updated: May 23, 2026

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice
09:13

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice

Published on: July 11, 2025

When MicroRNAs meet hypoxic pulmonary hypertension.

Ming-Ren Ma1, Xiao-Ke Wang1, Xiao Song1

  • 1Department of Cardiology, the 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou 730050, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 21, 2026
PubMed
Summary

MicroRNAs (miRNAs) are key regulators in hypoxic pulmonary hypertension (HPH) pathogenesis. Understanding their roles offers new diagnostic and therapeutic strategies for this severe cardiovascular disease.

Keywords:
BiomarkerEndothelial-Mesenchymal TransitionHypoxic Pulmonary HypertensionMetabolic ReprogrammingMicroRNAPulmonary Vascular RemodelingTargeted Therapy

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

Related Experiment Videos

Last Updated: May 23, 2026

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice
09:13

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice

Published on: July 11, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

Area of Science:

  • Cardiovascular Research
  • Pulmonary Medicine
  • Molecular Biology

Background:

  • Hypoxic pulmonary hypertension (HPH) is a severe cardiovascular condition linked to chronic hypoxia, causing pulmonary vascular remodeling and right heart failure.
  • Current HPH treatments are limited due to poor understanding of disease mechanisms and lack of targeted therapies.
  • MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and are implicated in HPH pathology.

Purpose of the Study:

  • To review recent advances in understanding the role of miRNAs in HPH pathogenesis.
  • To explore the clinical utility of miRNAs as biomarkers and therapeutic targets for HPH.
  • To identify current challenges and future directions in HPH research.

Main Methods:

  • Systematic review of current research on miRNAs in HPH.
  • Focus on miRNA regulatory networks in pulmonary vasoconstriction, vascular remodeling, inflammation, and metabolic reprogramming.
  • Analysis of clinical applications and translational prospects of miRNA-based strategies.

Main Results:

  • miRNAs play central roles in HPH processes like vasoconstriction, smooth muscle cell proliferation/apoptosis, endothelial-Mesenchymal transition (EndMT), inflammation, and metabolic changes.
  • miRNAs show potential as diagnostic and prognostic biomarkers for HPH.
  • Targeting miRNAs presents a promising therapeutic avenue for HPH.

Conclusions:

  • miRNAs are critical regulators in HPH development and progression.
  • Further research into miRNA networks can lead to novel diagnostic tools and effective treatments for HPH.
  • Translational studies are needed to fully realize the clinical potential of miRNAs in managing HPH.